Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
On first read I thought it was a reasonable summary with some interesting little additions to what we already know. On digesting the content I've come to the conclusion that despite wishful thinking there is no NDA in place and any discussions with the large pharmas are at very early stages ('come back when you've got something interesting to show us').Timelines are clearly slipping and Tim's 'significant growth in the next 12 months' looks much more like 12-24 months from now. Even if Sierra can pull off a deal on 737 there's no guarantee that the overdue milestones will land before the business runs out of cash. An awful lot can happen in 24 months (good and bad) but a prudent mgt team should be looking at an early exit for a sensible price, so I'm with ColdFish on this one. In addition I'm not expecting much from tomorrow's abstracts other than 'look what might be possible' with no impact on the SP. In fact I wouldn't be surprised to see 0.32 back on the board.
Coldfishpie-you've got it in one. All we ever get is technobabble and the usual "value for shareholders" carrot.
Let's hope Sierra can licence Chk1 before the end of 2020.
The directors consider that the cash held at the year-end, together with the proceeds of the placing received in July 2019, which amounted to £781,484 before expenses, will be sufficient to meet the forecast expenditure for at least one year from the date of signing the financial statements. In the event that there is a shortfall, the directors will implement cost savings to ensure that the cash resources last for this period of time. For this reason the financial statements have been prepared on a going concern basis.
Sorry...when i say they are dreaming it should be we are dreaming....they know the score exactly but of-course are playing the game.
Sell it or anything with value and retrieve some value for all that way...sar can talk as much as they like about big value lic deals but they are dreaming...they are not going to get that and will only get enough to cover salaries and bonuses for a few years as seen with chk1.
There are 3 outs here, a licensing deal gets the sp up to maybe 1p plus and we sell or we hold in the hope that things go well but thats a long arduous road or sell the asset and see some decent profit for us.
What works for them is what will be decided and we can FO!
Aurora not dead yet-
Aurora+FLT3 Inhibitors
While the Company focuses its research resources on completing the preclinical development of its TYK2/JAK1 programmes, it is seeking a licence partner for the Aurora+FLT3 programme and discussions are ongoing with a number of interested parties.
This is why SRI didn't apply for further funding-
Sareum has a co-development agreement with SRI International (Menlo Park, CA, USA), a non-profit scientific research institute, to develop TYK2 inhibitors in autoimmune diseases. SRI, working under a US Department of Defense ("DoD") grant, has completed a preclinical study using Sareum TYK2/JAK1 inhibitors in lupus disease models and the final report from this study is expected to be made public by the DoD in the near future.
At least we have confirmation on Chk1-
We continue to believe, based on the promising clinical and preclinical data generated to date, that Sierra has every chance of finding a suitable solution that will enable the development of SRA737 to advance. This, in due course, would lead to Sareum receiving the milestone payments under the licensing agreement between Sierra and CRT Pioneer Fund (CPF), the licensor of SRA737, with which Sareum has a Co-investment and Partnership agreement. We remain in dialogue with CPF to ensure we are informed of developments and are committed to updating shareholders and the market in general as and when the restrictions in the two agreements allow.
Sierra's decision does mean, however, that the clinical development milestones payments that Sareum could have anticipated if SRA737 development had progressed as previously planned, have now been delayed until Sierra finds a solution.
Achieving two near-term milestones in particular - dosing of the first patient with SRA737 in a Phase 1 trial in the US and/or dosing of the first patient in a randomised Phase 2 trial - would generate revenue to Sareum of around US$5.3 million. These previously confidential milestones were disclosed by Sierra for the first time in August 2019 and announced by the Company.
Hi All - looking forward to the abstract release tomorrow, this will be the first published acknowledgment from SAR of the compound selected as a result of the SRI experiments.
GLA
The two things I picked out were the TYK2 report due ‘in the near future” from the grant by DoD and also “The Directors will continue to review the potential higher value of a later-stage licensing deal versus the requirement for any extra funding.”